CEL-SCI (CVM): מחיר חזוי לרווח

A dedicated team of veteran scientists established the foundation of CEL-SCI Corporation (CVM). The company's expected P/E trend reflects current market dynamics, where 0.00 represents the latest level. Prospects depend on the success of Multikine and FDA decisions, as well as the implementation of eco-friendly chemical waste recycling systems within the laboratories.

CEL-SCI Corporation operations are constrained by a critical shortage of funds and capital dilution risks, making the company's 12-month forward P/E analysis a key tool for assessing business viability. This indicator compares the issuer's current market value with projected net income, allowing investors to determine the extent of the asset's overvaluation amid the uncertainty of clinical approvals.